---

---

for   entities : Takeda pharmaceutical company limited   

save search

---

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| Email alert Add to watchlist
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| Email alert Add to watchlist
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| Email alert Add to watchlist
granted approval cancer treatment for

---

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 0.0% | O: -0.11% H: 0.0% C: 0.0%
NBIX | News M | $140.11 4.83% 4.6% 1.6M |

Health Technology

| 0.0% | O: 5.43% H: 0.0% C: 0.0%
nbi-1065 positive for

---

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Published: 2024-04-22 (Crawled : 09:00) - prnewswire.com
SMFNF | News | $55.76 -1.2% 59 |

Finance

| -0.13% | O: -0.16% H: 3.14% C: 0.04%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| 0.32% | O: 0.63% H: 0.0% C: -0.31%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 1.17% | O: 0.8% H: 0.75% C: 0.38%
drug company for agreement

---

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| 1.6% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

---

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -5.58% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

---

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -8.24% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

---

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -8.24% | O: -0.07% H: 0.0% C: -0.96%
CNTG | $0.504 7.21% 6.73% 72K |

Commercial Services

| -32.86% | O: 1.43% H: 1.41% C: -1.41%
partnership genetic takeda disorders

---

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -7.03% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

---

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -6.18% | O: 0.07% H: 0.46% C: 0.42%
fda first treatment

---

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -5.65% | O: 0.07% H: 0.42% C: 0.07%
NBIX | News M | $140.11 4.83% 4.6% 1.6M |

Health Technology

| -6.51% | O: -5.57% H: 6.04% C: 0.96%
financial results

---

Announcing Cognizant Flowsource™, a generative AI-enabled platform for powering modern engineering
Published: 2024-02-01 (Crawled : 05:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -8.49% | O: 0.48% H: 0.0% C: -1.98%
CTSH | $67.75 -0.66% -0.66% 2.8M |

Technology Services

| -11.57% | O: 0.3% H: 0.78% C: 0.69%
cognizant platform

---

Takeda Named Global Top Employer for Seventh Consecutive Year
Published: 2024-01-18 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -10.09% | O: -0.13% H: 0.27% C: 0.2%
year global

---

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -2.41% | O: 2.05% H: 0.29% C: 0.0%
livtencity approval cytomegalovirus treatment china

---

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare form of Emphysema
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -3.05% | O: 0.36% H: 0.14% C: -1.01%
rare services glassia contract treatment blood

---

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -4.91% | O: -0.64% H: 0.21% C: -1.79%
hyqvia chmp positive therapy

---

Insomnia Therapeutics Market to grow by USD 1 billion from 2022-2027 | North America to account for 60% of market growth - Technavio
Published: 2023-11-27 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -2.28% | O: -1.89% H: 0.02% C: 0.02%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -22.27% | O: -4.49% H: 6.23% C: 3.42%
VTRS | News A | $11.36 0.98% 0.97% 4.7M |

Health Technology

| 20.45% | O: -0.21% H: 0.21% C: -1.93%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -5.05% | O: -0.07% H: 0.28% C: 0.21%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| 4.24% | O: -0.24% H: 0.03% C: -0.39%
VNDA | $4.63 -3.54% -3.67% 1.4M |

Health Technology

| 41.99% | O: 2.81% H: 0.0% C: -3.01%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -2.89% | O: -1.41% H: 0.87% C: 0.0%
america therapeutics growth market

---

FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -4.64% | O: 0.07% H: 0.57% C: 0.0%
cancer treatment

---

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Published: 2023-11-17 (Crawled : 15:30) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -2.62% | O: 1.75% H: 0.32% C: -0.07%
takhzyro label update group

---

COVID-19 Challenges Drive the Need for Resilient Supply Chains and Digital Healthcare in the Anti-Epileptic Drugs Market, Shaping the Post-Pandemic Landscape
Published: 2023-11-06 (Crawled : 19:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630 |

Health Technology

| 18.09% | O: 0.41% H: 0.0% C: 0.0%
VTRS | News A | $11.36 0.98% 0.97% 4.7M |

Health Technology

| 22.15% | O: 0.11% H: 0.33% C: -0.98%
TEVA | $13.01 1.01% 0.0% 8.9M |

Health Technology

| 42.32% | O: 0.22% H: 1.49% C: -0.33%
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -2.55% | O: 0.44% H: 0.22% C: 0.07%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| 1.41% | O: 0.24% H: 0.18% C: 0.16%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -1.68% | O: 0.18% H: 0.0% C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M |

Health Technology

| 16.67% | O: 0.55% H: 0.3% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| 12.02% | O: -0.42% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 1.31% | O: -1.32% H: 0.0% C: 0.0%
covid-19

---

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M |

Health Technology

| -10.4% | O: -1.61% H: 0.14% C: -0.27%
cd30 adcetris treatment

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---